Venus Remedies Share Price

Venus Remedies

CMP as on 23-May-22 15:55

₹ 239.50
-4.40 -1.8%

Open

₹ 249.00

Turnover (lac)

₹ 24

Prev. Close

₹ 243.90

Day's Vol (shares)

₹ 10,166

Day's Range (₹)

₹ 237.00
₹ 249.00

CMP as on23-May-22 15:28

₹ 236.30
-7.2 -2.96%

Open

₹ 243.45

Turnover (lac)

₹ 21

Prev. Close

₹ 243.50

Day's Vol (shares)

₹ 1,074

Day's Range

₹ 236.30
₹ 243.70

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 20-Jan-2022 - -
VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2022 inter alia to consider and approve Meeting of Board of Directors is scheduled to be held on 31st January 2022 inter alia consider and approve Unaudited Financial Results for the quarter ended on 31st December 2021 and any other business with the permission of Chair. This has reference to the meeting of Board of Directors held on 31st January 2022 inter alia considered and approved the Unaudited Financial Results for the quarter and nine months ended on 31st December 2021 along with Limited Review report. (As Per BSE Announcement Dated on 31.01.2022)
Board Meeting - 23-Dec-2021 - -
VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/12/2021 inter alia to consider and approve Board meeting scheduled to be held on 30.12.2021 to consider the appointment of additional director- Independent director. This has reference to the meeting of Board of Directors held on 30th December 2021 inter alia considered and approved the appointment of Dr. Savita Gupta as Additional Director (Non- Executive Independent Director) w.e.f. 30th December 2021 to hold office till the conclusion of the next General Meeting and will be appointed as regular Independent Non -Executive Director for five consecutive years, subject to approval of members in the next General Meeting. (As per BSE Announcement Dated on 30/12/2021)
Board Meeting - 18-Oct-2021 - -
Quarterly Results This has reference to the meeting of Board of Directors held on 30th October 2021 inter alia considered and approved the Unaudited Financial Results for the quarter ended on 30.09.2021 along with Limited Review report. (As Per BSE Announcement Dated on 30/10/2021)
Board Meeting - 04-Aug-2021 - -
VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2021 ,inter alia, to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on Thursday, 12th August 2021 inter alia consider and approve as below: 1. Unaudited Financial Results for the quarter ended on 30th June 2021 2. Finalization of date of 32nd Annual General Meeting of the Company. 3. To consider draft notice of AGM along with draft Directors Report and Corporate Governance Report for FY 2020-21. 4. Any other business with the permission of Chair. Further, as informed vide letter dated 30.06.2021, the trading window would remain closed till 48 hours from the publication of financial results for designated persons and their immediate relatives, in view of the aforesaid Board meeting. Outcome of Board Meeting dated 12.08.2021 as enclosed. (As per BSE Announcement Dated on 12/8/2021)
Board Meeting - 24-May-2021 - -
VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/05/2021 ,inter alia, to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on 31st May 2021 to inter alia consider and approve as below: 1 To consider and approve Audited Financial Results for the quarter and year ended on 31st March 2021. 2 To consider and approve the allotment of 10,25,000 equity shares on conversion of 10,25,000 fully convertible warrants. 3 Any other business with the permission of Chair. This has reference to the meeting of Board of Directors held on 31st May, 2021 inter alia considered and approved as below: 1. Audited Financial Results for the quarter and year ended on 31st March, 2021 along with Audit report. 2. Allotment of 10,25,000 equity shares of face value of Rs.10 each upon conversion of warrants on preferential basis to promoters of the Company. Allotment of 10,25,000 equity shares of face value of Rs.10 each upon conversion of warrants on preferential basis to promoters of the Company. (As per BSE Announcement Dated on 31/05/2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity